# A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19

> **NCT04558021** · PHASE3 · UNKNOWN · sponsor: **Imuneks Farma ilac San. Tic. A.S.** · enrollment: 200 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Niclosamide suspension
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04558021
- **Lead sponsor:** Imuneks Farma ilac San. Tic. A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-08
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-02-14
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04558021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04558021, "A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04558021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*